CPRX Q3 2025 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$148M+15.3% YoY

Gross Profit

$123M82.9% margin

Operating Income

$66M44.7% margin

Net Income

$53M35.6% margin

EPS (Diluted)

$0.42

QoQ Revenue Growth

+1.2%

Cash Flow

Operating Cash Flow

$32M

Free Cash Flow

$32M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$131M

Stockholders' Equity

$920M

Cash & Equivalents

$690M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$148M	$129M	+15.3%
Gross Profit	$123M	$109M	+12.5%
Operating Income	$66M	$51M	+30.2%
Net Income	$53M	$44M	+20.3%

Revenue Segments

Product Revenue Net

$148M100%

License And Other Revenue

$27,0000%